Concepts (226)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antineoplastic Agents | 9 | 2016 | 756 | 1.610 |
Why?
|
| Colonoscopy | 4 | 2016 | 98 | 1.120 |
Why?
|
| Sulfones | 3 | 2015 | 40 | 1.020 |
Why?
|
| Adenomatous Polyposis Coli | 7 | 2018 | 27 | 0.990 |
Why?
|
| Colorectal Neoplasms | 5 | 2020 | 413 | 0.970 |
Why?
|
| Acrylonitrile | 2 | 2015 | 3 | 0.960 |
Why?
|
| Peritoneal Neoplasms | 3 | 2012 | 15 | 0.920 |
Why?
|
| Colonic Neoplasms | 6 | 2012 | 181 | 0.900 |
Why?
|
| Receptor, erbB-2 | 3 | 2012 | 122 | 0.860 |
Why?
|
| Gastrointestinal Hemorrhage | 3 | 2007 | 26 | 0.830 |
Why?
|
| Hedgehog Proteins | 2 | 2014 | 45 | 0.780 |
Why?
|
| Carcinoma | 2 | 2012 | 94 | 0.780 |
Why?
|
| Intestinal Mucosa | 2 | 2014 | 115 | 0.750 |
Why?
|
| Health Personnel | 1 | 2020 | 200 | 0.650 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2018 | 178 | 0.640 |
Why?
|
| Primary Health Care | 1 | 2020 | 283 | 0.620 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2020 | 781 | 0.600 |
Why?
|
| Microfilament Proteins | 2 | 2014 | 64 | 0.580 |
Why?
|
| Adenoma | 5 | 2010 | 89 | 0.580 |
Why?
|
| Apoptosis | 8 | 2015 | 1317 | 0.570 |
Why?
|
| Duodenal Neoplasms | 1 | 2016 | 5 | 0.570 |
Why?
|
| Ovarian Neoplasms | 3 | 2015 | 303 | 0.570 |
Why?
|
| Antibodies, Monoclonal | 3 | 2007 | 282 | 0.550 |
Why?
|
| Pancreatic Neoplasms | 2 | 2015 | 106 | 0.550 |
Why?
|
| MicroRNAs | 1 | 2020 | 386 | 0.540 |
Why?
|
| Rectal Diseases | 2 | 2005 | 4 | 0.530 |
Why?
|
| Receptors, Death Domain | 2 | 2011 | 2 | 0.510 |
Why?
|
| Nitriles | 2 | 2012 | 66 | 0.500 |
Why?
|
| Peutz-Jeghers Syndrome | 2 | 2011 | 2 | 0.490 |
Why?
|
| Drug Design | 1 | 2015 | 154 | 0.480 |
Why?
|
| Neoplasms | 4 | 2012 | 1033 | 0.470 |
Why?
|
| Early Detection of Cancer | 1 | 2016 | 292 | 0.450 |
Why?
|
| Mass Screening | 1 | 2016 | 427 | 0.420 |
Why?
|
| Humans | 30 | 2020 | 34853 | 0.420 |
Why?
|
| CASP8 and FADD-Like Apoptosis Regulating Protein | 1 | 2011 | 8 | 0.410 |
Why?
|
| Histones | 1 | 2012 | 177 | 0.390 |
Why?
|
| Gene Expression Regulation | 2 | 2014 | 968 | 0.370 |
Why?
|
| Clinical Trials as Topic | 2 | 2011 | 195 | 0.360 |
Why?
|
| Female | 16 | 2020 | 19873 | 0.360 |
Why?
|
| Mice | 9 | 2015 | 5668 | 0.350 |
Why?
|
| Hawaii | 3 | 2020 | 1878 | 0.330 |
Why?
|
| Down-Regulation | 3 | 2011 | 420 | 0.330 |
Why?
|
| Family | 2 | 2010 | 162 | 0.320 |
Why?
|
| Gastrostomy | 1 | 2007 | 7 | 0.310 |
Why?
|
| Foreign Bodies | 1 | 2007 | 6 | 0.310 |
Why?
|
| Gene Deletion | 2 | 2010 | 156 | 0.300 |
Why?
|
| Enteral Nutrition | 1 | 2007 | 16 | 0.300 |
Why?
|
| Deglutition Disorders | 1 | 2007 | 18 | 0.300 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2007 | 56 | 0.290 |
Why?
|
| Animals | 11 | 2015 | 14307 | 0.290 |
Why?
|
| Cell Proliferation | 5 | 2015 | 1149 | 0.280 |
Why?
|
| Malnutrition | 1 | 2006 | 45 | 0.280 |
Why?
|
| Middle Aged | 10 | 2020 | 9642 | 0.280 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2008 | 528 | 0.280 |
Why?
|
| Follow-Up Studies | 5 | 2020 | 964 | 0.270 |
Why?
|
| Mice, Nude | 4 | 2012 | 323 | 0.270 |
Why?
|
| Cell Line, Tumor | 5 | 2015 | 2128 | 0.270 |
Why?
|
| Integrin alpha5beta1 | 1 | 2005 | 5 | 0.270 |
Why?
|
| Colonic Diseases | 1 | 2004 | 11 | 0.260 |
Why?
|
| Male | 13 | 2020 | 18870 | 0.260 |
Why?
|
| Genes, APC | 3 | 2016 | 14 | 0.260 |
Why?
|
| Caco-2 Cells | 3 | 2012 | 48 | 0.250 |
Why?
|
| Sulindac | 3 | 2018 | 7 | 0.240 |
Why?
|
| HT29 Cells | 2 | 2015 | 40 | 0.230 |
Why?
|
| Signal Transduction | 6 | 2014 | 1802 | 0.230 |
Why?
|
| Aged | 6 | 2020 | 6448 | 0.210 |
Why?
|
| Retrospective Studies | 4 | 2016 | 1961 | 0.210 |
Why?
|
| RNA, Messenger | 3 | 2014 | 1152 | 0.190 |
Why?
|
| Structure-Activity Relationship | 2 | 2015 | 376 | 0.190 |
Why?
|
| Prognosis | 2 | 2020 | 707 | 0.190 |
Why?
|
| Liver Cirrhosis | 1 | 2020 | 51 | 0.180 |
Why?
|
| Japan | 1 | 2020 | 296 | 0.180 |
Why?
|
| Cell Adhesion | 2 | 2011 | 209 | 0.180 |
Why?
|
| Risk Reduction Behavior | 1 | 2020 | 121 | 0.180 |
Why?
|
| Disease Progression | 2 | 2020 | 580 | 0.170 |
Why?
|
| Cell Differentiation | 2 | 2014 | 562 | 0.160 |
Why?
|
| Cell Division | 2 | 2012 | 296 | 0.160 |
Why?
|
| Case-Control Studies | 1 | 2020 | 1056 | 0.150 |
Why?
|
| Caspases | 2 | 2009 | 132 | 0.140 |
Why?
|
| Adult | 9 | 2018 | 11034 | 0.140 |
Why?
|
| Neoplasm Transplantation | 2 | 2012 | 114 | 0.130 |
Why?
|
| Integrases | 1 | 2014 | 27 | 0.130 |
Why?
|
| Immunoenzyme Techniques | 1 | 2014 | 105 | 0.130 |
Why?
|
| Transfection | 2 | 2006 | 496 | 0.130 |
Why?
|
| Cell Nucleus | 3 | 2012 | 351 | 0.130 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2015 | 984 | 0.120 |
Why?
|
| Neoplasm Seeding | 1 | 2013 | 4 | 0.120 |
Why?
|
| Aged, 80 and over | 3 | 2010 | 2333 | 0.120 |
Why?
|
| Catheter Ablation | 1 | 2013 | 31 | 0.120 |
Why?
|
| Liver Diseases | 1 | 2013 | 31 | 0.120 |
Why?
|
| Molecular Structure | 1 | 2015 | 467 | 0.110 |
Why?
|
| Liver Transplantation | 1 | 2013 | 30 | 0.110 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2014 | 605 | 0.110 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2013 | 133 | 0.110 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2012 | 40 | 0.110 |
Why?
|
| Peritoneum | 1 | 2012 | 8 | 0.110 |
Why?
|
| Blotting, Western | 1 | 2014 | 834 | 0.110 |
Why?
|
| Risk Factors | 4 | 2013 | 3414 | 0.110 |
Why?
|
| Coculture Techniques | 1 | 2012 | 96 | 0.100 |
Why?
|
| Mice, Knockout | 1 | 2014 | 897 | 0.100 |
Why?
|
| Phosphorylation | 2 | 2005 | 878 | 0.100 |
Why?
|
| Ovary | 1 | 2012 | 101 | 0.100 |
Why?
|
| Epithelium | 1 | 2011 | 74 | 0.100 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2013 | 147 | 0.100 |
Why?
|
| Liver Neoplasms | 1 | 2013 | 195 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 13 | 1 | 2010 | 10 | 0.100 |
Why?
|
| Cells, Cultured | 1 | 2014 | 1442 | 0.100 |
Why?
|
| Promoter Regions, Genetic | 1 | 2012 | 484 | 0.090 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2010 | 58 | 0.090 |
Why?
|
| Porifera | 1 | 2009 | 8 | 0.090 |
Why?
|
| RNA, Small Interfering | 1 | 2011 | 391 | 0.090 |
Why?
|
| Alkaloids | 1 | 2009 | 38 | 0.090 |
Why?
|
| Imidazoles | 1 | 2009 | 124 | 0.080 |
Why?
|
| Neoplasm Metastasis | 1 | 2009 | 211 | 0.080 |
Why?
|
| Age Distribution | 1 | 2008 | 223 | 0.080 |
Why?
|
| Sex Distribution | 1 | 2008 | 212 | 0.080 |
Why?
|
| Genetic Testing | 2 | 2005 | 71 | 0.080 |
Why?
|
| Rats | 1 | 2014 | 3261 | 0.080 |
Why?
|
| Hepatocyte Nuclear Factor 3-beta | 1 | 2006 | 1 | 0.080 |
Why?
|
| Gastrointestinal Contents | 1 | 2006 | 2 | 0.080 |
Why?
|
| Enterocytes | 1 | 2006 | 4 | 0.070 |
Why?
|
| TCF Transcription Factors | 1 | 2006 | 14 | 0.070 |
Why?
|
| Microvilli | 1 | 2006 | 9 | 0.070 |
Why?
|
| Ki-67 Antigen | 1 | 2006 | 32 | 0.070 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2006 | 17 | 0.070 |
Why?
|
| Macular Degeneration | 1 | 2007 | 27 | 0.070 |
Why?
|
| United States | 2 | 2008 | 3894 | 0.070 |
Why?
|
| Hyperplasia | 1 | 2006 | 38 | 0.070 |
Why?
|
| Intestines | 1 | 2006 | 63 | 0.070 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2007 | 157 | 0.070 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2006 | 18 | 0.070 |
Why?
|
| Mitochondria | 1 | 2010 | 454 | 0.070 |
Why?
|
| Hamartoma Syndrome, Multiple | 1 | 2005 | 2 | 0.070 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2006 | 184 | 0.070 |
Why?
|
| Agar | 1 | 2005 | 8 | 0.070 |
Why?
|
| Biotinylation | 1 | 2005 | 9 | 0.070 |
Why?
|
| RNA Processing, Post-Transcriptional | 1 | 2005 | 26 | 0.070 |
Why?
|
| Fissure in Ano | 1 | 2004 | 1 | 0.070 |
Why?
|
| Hemorrhoids | 1 | 2004 | 1 | 0.070 |
Why?
|
| Hemostasis, Endoscopic | 1 | 2004 | 2 | 0.070 |
Why?
|
| Intestinal Polyps | 1 | 2004 | 4 | 0.070 |
Why?
|
| Ulcer | 1 | 2004 | 5 | 0.070 |
Why?
|
| Diverticulum, Colon | 1 | 2004 | 3 | 0.070 |
Why?
|
| Blotting, Northern | 1 | 2005 | 139 | 0.070 |
Why?
|
| Angiodysplasia | 1 | 2004 | 3 | 0.070 |
Why?
|
| Medical Records | 1 | 2004 | 37 | 0.060 |
Why?
|
| Immunoprecipitation | 1 | 2005 | 126 | 0.060 |
Why?
|
| Immunoblotting | 1 | 2005 | 170 | 0.060 |
Why?
|
| Cytoplasm | 1 | 2005 | 135 | 0.060 |
Why?
|
| Lysosomes | 1 | 2005 | 80 | 0.060 |
Why?
|
| Mice, Transgenic | 1 | 2006 | 608 | 0.060 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2005 | 168 | 0.060 |
Why?
|
| Green Fluorescent Proteins | 1 | 2005 | 200 | 0.060 |
Why?
|
| Extracellular Matrix | 1 | 2005 | 111 | 0.060 |
Why?
|
| Adenomatous Polyposis Coli Protein | 1 | 2004 | 9 | 0.060 |
Why?
|
| Epidermal Growth Factor | 1 | 2004 | 63 | 0.060 |
Why?
|
| Colitis | 1 | 2004 | 64 | 0.060 |
Why?
|
| Protein Structure, Tertiary | 1 | 2005 | 383 | 0.060 |
Why?
|
| Introns | 1 | 2004 | 67 | 0.060 |
Why?
|
| Prevalence | 1 | 2008 | 1425 | 0.060 |
Why?
|
| Ubiquitin | 1 | 2004 | 76 | 0.060 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2004 | 121 | 0.060 |
Why?
|
| Cell Membrane | 1 | 2005 | 360 | 0.060 |
Why?
|
| Cytoskeletal Proteins | 1 | 2003 | 97 | 0.060 |
Why?
|
| Trans-Activators | 1 | 2003 | 167 | 0.050 |
Why?
|
| Jews | 1 | 2002 | 4 | 0.050 |
Why?
|
| Adenomatous Polyps | 1 | 2002 | 12 | 0.050 |
Why?
|
| Transcription, Genetic | 1 | 2005 | 550 | 0.050 |
Why?
|
| Age Factors | 1 | 2004 | 1007 | 0.050 |
Why?
|
| Breast Neoplasms | 1 | 2012 | 1426 | 0.050 |
Why?
|
| Time Factors | 1 | 2005 | 1681 | 0.050 |
Why?
|
| Treatment Outcome | 2 | 2018 | 1349 | 0.050 |
Why?
|
| Phenotype | 3 | 2010 | 650 | 0.040 |
Why?
|
| Utah | 2 | 2010 | 9 | 0.040 |
Why?
|
| Pedigree | 2 | 2010 | 64 | 0.040 |
Why?
|
| Colectomy | 2 | 2004 | 16 | 0.030 |
Why?
|
| Needles | 1 | 2013 | 8 | 0.030 |
Why?
|
| Survival Rate | 1 | 2013 | 310 | 0.030 |
Why?
|
| Adamantane | 1 | 2010 | 8 | 0.020 |
Why?
|
| Hepatocyte Nuclear Factor 4 | 1 | 2010 | 5 | 0.020 |
Why?
|
| Cinnamates | 1 | 2010 | 5 | 0.020 |
Why?
|
| Cell Respiration | 1 | 2010 | 33 | 0.020 |
Why?
|
| Cytochromes c | 1 | 2010 | 45 | 0.020 |
Why?
|
| Chromosome Mapping | 1 | 2010 | 159 | 0.020 |
Why?
|
| Protein Stability | 1 | 2010 | 40 | 0.020 |
Why?
|
| Databases, Genetic | 1 | 2010 | 90 | 0.020 |
Why?
|
| Retinoids | 1 | 2010 | 28 | 0.020 |
Why?
|
| Genetic Markers | 1 | 2010 | 118 | 0.020 |
Why?
|
| Haplotypes | 1 | 2010 | 152 | 0.020 |
Why?
|
| Hepatocytes | 1 | 2010 | 74 | 0.020 |
Why?
|
| Neoplasms, Experimental | 1 | 2009 | 36 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2010 | 139 | 0.020 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2009 | 107 | 0.020 |
Why?
|
| Protein Transport | 1 | 2010 | 286 | 0.020 |
Why?
|
| Cell Culture Techniques | 1 | 2009 | 136 | 0.020 |
Why?
|
| Fibroblasts | 1 | 2010 | 252 | 0.020 |
Why?
|
| Cell Cycle | 1 | 2009 | 309 | 0.020 |
Why?
|
| Reactive Oxygen Species | 1 | 2010 | 416 | 0.020 |
Why?
|
| Incidental Findings | 1 | 2006 | 10 | 0.020 |
Why?
|
| Protein Binding | 1 | 2010 | 913 | 0.020 |
Why?
|
| Back Pain | 1 | 2006 | 19 | 0.020 |
Why?
|
| Abdominal Pain | 1 | 2006 | 24 | 0.020 |
Why?
|
| DNA Glycosylases | 1 | 2005 | 16 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2006 | 206 | 0.020 |
Why?
|
| Endoscopy, Digestive System | 1 | 2004 | 3 | 0.020 |
Why?
|
| Rectum | 1 | 2004 | 22 | 0.020 |
Why?
|
| Physical Examination | 1 | 2004 | 40 | 0.020 |
Why?
|
| Registries | 1 | 2006 | 330 | 0.020 |
Why?
|
| Family Health | 1 | 2004 | 47 | 0.020 |
Why?
|
| Adolescent | 2 | 2005 | 5035 | 0.020 |
Why?
|
| Leupeptins | 1 | 2003 | 11 | 0.020 |
Why?
|
| Germ-Line Mutation | 1 | 2004 | 51 | 0.010 |
Why?
|
| Cysteine Proteinase Inhibitors | 1 | 2003 | 21 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2004 | 322 | 0.010 |
Why?
|
| Cysteine Endopeptidases | 1 | 2003 | 57 | 0.010 |
Why?
|
| Multienzyme Complexes | 1 | 2003 | 63 | 0.010 |
Why?
|
| beta Catenin | 1 | 2003 | 46 | 0.010 |
Why?
|
| Caspase 3 | 1 | 2003 | 194 | 0.010 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2003 | 109 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 2003 | 480 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2004 | 430 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2004 | 555 | 0.010 |
Why?
|
| Base Sequence | 1 | 2004 | 932 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 2003 | 396 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2004 | 1490 | 0.010 |
Why?
|
| Child | 1 | 2005 | 2875 | 0.010 |
Why?
|